141 related articles for article (PubMed ID: 35593342)
41. Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.
Møller MB; Nielsen O; Pedersen NT
Histopathology; 2002 Oct; 41(4):322-30. PubMed ID: 12383214
[TBL] [Abstract][Full Text] [Related]
42. [Progress of study on survivin in diffuse large B-cell lymphoma--review].
Dou HJ; Hu JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1487-90. PubMed ID: 19099670
[TBL] [Abstract][Full Text] [Related]
43. [Clinical and prognostic analysis of 101 cases of primary gastrointestinal non-Hodgkin's lymphoma].
Song LN; Cen XN; Ou JP; Liang ZY; Qiu ZX; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Yin Y; Sun YH; Liu W; Wang Q; Wang LH; Wang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):387-91. PubMed ID: 23628038
[TBL] [Abstract][Full Text] [Related]
44. Mantle cell lymphoma and diffuse large B-cell lymphoma of the testis: a unique case of composite non-Hodgkin lymphoma.
Andhavarapu S; Crozier JA; Jiang L; Sher T
Eur J Haematol; 2014 Dec; 93(6):537-42. PubMed ID: 24750331
[TBL] [Abstract][Full Text] [Related]
45. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
46. Expression of Myc target gene mina53 in subtypes of human lymphoma.
Teye K; Arima N; Nakamura Y; Sakamoto K; Sueoka E; Kimura H; Tsuneoka M
Oncol Rep; 2007 Oct; 18(4):841-8. PubMed ID: 17786344
[TBL] [Abstract][Full Text] [Related]
47. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma.
Molina A
Annu Rev Med; 2008; 59():237-50. PubMed ID: 18186705
[TBL] [Abstract][Full Text] [Related]
48. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review.
Decruyenaere P; Offner F; Vandesompele J
Exp Hematol Oncol; 2021 Feb; 10(1):13. PubMed ID: 33593440
[TBL] [Abstract][Full Text] [Related]
49. Role of local treatment in primary breast B-cell non-Hodgkin's lymphoma: a propensity score matching-based analysis from SEER database.
Zhang M; Liu N; Wang BY; Zhang J; Zhao A; Yang J; Yang J
Eur Rev Med Pharmacol Sci; 2022 Jan; 26(1):22-31. PubMed ID: 35049015
[TBL] [Abstract][Full Text] [Related]
50. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
51. Diffuse large B-cell lymphoma and polycythemia vera discovered at the onset - a rare association and its possible importance in lymphoma prognosis.
Popov VM; Dobrea CM; Popescu M; Pleşea IE; Grigorean VT; Sinescu RD; Strâmbu VD
Rom J Morphol Embryol; 2016; 57(1):313-8. PubMed ID: 27151728
[TBL] [Abstract][Full Text] [Related]
52. Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma.
Lin H; Sun XF; Zhen ZJ; Xia Y; Ling JY; Huang HQ; Xia ZJ; Lin TY
Ai Zheng; 2009 Nov; 28(11):1186-92. PubMed ID: 19895740
[TBL] [Abstract][Full Text] [Related]
53. Clinical features and treatment outcomes of non-Hodgkin's lymphomas involving rare extranodal sites: a single-center experience.
Yun J; Kim SJ; Kim JA; Kong JH; Lee SH; Kim K; Ko YH; Kim WS
Acta Haematol; 2010; 123(1):48-54. PubMed ID: 19955711
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms.
Lee SS; Cho KJ; Kim CW; Kang YK
Histopathology; 1999 Oct; 35(4):345-54. PubMed ID: 10564389
[TBL] [Abstract][Full Text] [Related]
55. Diffuse large B-cell lymphoma.
Li S; Young KH; Medeiros LJ
Pathology; 2018 Jan; 50(1):74-87. PubMed ID: 29167021
[TBL] [Abstract][Full Text] [Related]
56. Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey.
Mertsoylu H; Muallaoglu S; Besen AA; Erdogdu S; Sezer A; Sedef AM; Kose F; Arican A; Ozyilkan O
Asian Pac J Cancer Prev; 2014; 15(17):7207-11. PubMed ID: 25227815
[TBL] [Abstract][Full Text] [Related]
57. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
[TBL] [Abstract][Full Text] [Related]
58. Intra-tumour heterogeneity of diffuse large B-cell lymphoma involves the induction of diversified stroma-tumour interfaces.
Sangaletti S; Iannelli F; Zanardi F; Cancila V; Portararo P; Botti L; Vacca D; Chiodoni C; Di Napoli A; Valenti C; Rizzello C; Vegliante MC; Pisati F; Gulino A; Ponzoni M; Colombo MP; Tripodo C
EBioMedicine; 2020 Nov; 61():103055. PubMed ID: 33096480
[TBL] [Abstract][Full Text] [Related]
59. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
60. JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide.
Xu PP; Sun YF; Fang Y; Song Q; Yan ZX; Chen Y; Jiang XF; Fei XC; Zhao Y; Leboeuf C; Li B; Wang CF; Janin A; Wang L; Zhao WL
Sci Rep; 2017 Aug; 7(1):7433. PubMed ID: 28785100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
